Rossari Biotech shares surge 9%, hit highest level since listing

Thus far in the month of April, the stock has soared 16 per cent in four trading days, after the company announced full commissioning of its Greenfield manufacturing facility at Dahej, Gujarat

markets, stock market, sensex, correction, nifty, shares, growth, profit, economy, gain
SI Reporter Mumbai
2 min read Last Updated : Apr 07 2021 | 10:55 AM IST
Shares of Rossari Biotech rallied 9 per cent to Rs 1,199 on the BSE in intraday trade on Wednesday. This is also the stock's highest level since listing on the bourses on July 23 last year. It surpassed its previous high of Rs 1,145.65, hit on February 19.

Thus far in the month of April, the specialty chemicals company's stock has soared 16 per cent in the four trading days, after the company announced full commissioning of its Greenfield manufacturing facility at Dahej, Gujarat.

The Greenfield facility will have a total installed capacity 132,500 MTPA, enhancing the total capacity of Rossari by 2.1x to 252,500 MTPA. A strong upcoming pipeline of new product launches and new business lines within the four core chemistries should enable the Company to sustainably ramp-up utilization levels at the Dahej unit over the next 3-4 years, Rossari Biotech said in a press release.

Meanwhile, the company’s board, on March 23, gave a go-ahead to issue equity shares aggregating to Rs 300 crore on a preferential basis, subject to necessary approvals. The company said its board of directors approved the issuance of up to 3.01 million equity shares on a preferential basis and determined a floor price of Rs 996 per equity share or such a higher price, aggregating to Rs 300 crore.

The proposed issue will bring onboard high-quality and marquee shareholders of scale and repute. The funds from this issue, if approved, will further strengthen the company’s balance sheet profile and will also augment the financial flexibility to address medium-to-long-term growth prospects. The proposed investors include SBI Mutual Fund (through various schemes), Malabar Select Fund, Malabar India Fund, India Acorn Fund, Ramesh Siyani and Arpit Khandelwal, the company said in a separate exchange filing.

Rossari proposes to utilise the net proceeds to evaluate and invest in inorganic growth opportunities, within its core chemistries, with a view to diversify its product portfolio, expand the geographical reach and augment end-user industry applications. This will further enable the company to build a strong upcoming pipeline of new products, with impetus on sustainability and environment-friendliness, it said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Rossari BiotechBuzzing stocksMarkets

Next Story